Physician profile
Stephan Hambaz
NPI 1972918001
$729.48
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $568 · 2020: $135 · 2022: $26.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $146.09 | 2019 | |
| Allergan, INC. | $144.29 | 2019 | |
| Merck Sharp & Dohme LLC | $136.75 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $91.20 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.95 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $28.67 | 2019 | |
| Abbvie INC. | $26.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.84 | 2019 | |
| Shire North American Group INC | $21.41 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $20.20 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.75 | 2019 | |
| Janssen Biotech, INC. | $13.72 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.71 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Hambaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.